NCT02061202View on ClinicalTrials.gov

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Sickle Cell Disease
Interventions
DRUG

Mometasone Furoate

inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks

DRUG

Placebo

placebo training inhaler with the same instructions as the experimental group.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Jeffrey Glassberg

OTHER

NCT02061202 - Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter